Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DP17AI
|
|||
| Drug Name |
Palomid-529
|
|||
| Synonyms |
Palomid 529; 914913-88-5; P529; Palomid 529 (P529); 8-(1-Hydroxyethyl)-2-methoxy-3-((4-methoxybenzyl)oxy)-6H-benzo[c]chromen-6-one; SG 00529; SG-00529; P-529; 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one; UNII-XV9409EWG4; 6H-Dibenzo(b,d)pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-; 8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-6H-benzo[c]chromen-6-one; Palomid529; 6H-Dibenzo[b,d]pyran-6-one, 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]-; 8-(1-Hydroxyethyl)-2-methoxy-3-[(4-methoxybenzyl)oxy]-6H-benzo[c]chromen-6-one; RES-529; XV9409EWG4; Palomid 529,P529; cc-513; MLS006011187; Palomid 529 - P529; SCHEMBL290034; C22H26Cl2N2O8; CHEMBL2141712; EX-A254; QCR-215; SYN5215; BCPP000131; HMS3655L14; HMS3673G05; AMY22735; BCP02474; ABP000907; MFCD18633224; NSC775306; NSC801008; s2238; 8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo(c)chromen-6-one; AKOS024463339; ACN-030389; BCP9001049; CCG-268719; CS-0258; DB12812; NSC-775306; NSC-801008; Palomid 529 (P529) /P529; SB16564; SG00529; 8-(1-hydroxyethyl)-2-methoxy-3-((4-methoxyphenyl)methoxy)-6h-dibenzo(b,d)pyran-6-one; NCGC00263125-01; NCGC00263125-10; AC-31523; AK160239; AS-16573; HY-14581; SMR004702956; AB0008147; SW219676-1; Y0291; W-5766; J-519339; Q27294013
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22O6
|
|||
| Canonical SMILES |
CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O
|
|||
| InChI |
1S/C24H22O6/c1-14(25)16-6-9-18-19-11-22(28-3)23(12-21(19)30-24(26)20(18)10-16)29-13-15-4-7-17(27-2)8-5-15/h4-12,14,25H,13H2,1-3H3
|
|||
| InChIKey |
YEAHTLOYHVWAKW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 914913-88-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mammalian target of rapamycin complex 1 (mTORC1) | Target Info | Inhibitor | [2] |
| Target of rapamycin complex 2 MAPKAP1 (MTORC2) | Target Info | Inhibitor | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01033721) Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (P52901). U.S. National Institutes of Health. | |||
| REF 2 | Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.